Articles

The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.

Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best metric to evaluate them?

Helping people benefit from the programs for which they are eligible could have a significant impact on the share of Americans with health coverage, possibly making the idea of automatic enrollment into coverage attractive across the political spectrum.

Do the clinical gains offered by these drugs in treating specific cancer indications justify the price increases? Schaeffer Center researchers Alice Chen and Dana Goldman explore how we might measure the value of these drugs.

In a panel discussion, Schaeffer experts outline policy approaches to improve the current healthcare system, following keynote remarks by California Attorney General Xavier Becerra.

This blog presents new evidence on observed changes in provider network breadth after the implementation of California’s 2017 law.

Less than 5 percent of state drug pricing laws passed between 2015 and 2018 will provide new information about pricing within the pharmaceutical distribution system.

In Texas v. U.S., Texas and a number of other states have sued the federal government, arguing that the entire ACA should be struck down. So, where does your state stand in Texas v. U.S.?

This piece describes the claim DOJ has made in regards to Texas v. U.S., attempts to unpack some of the complicated policy implications, and then considers the relevant legal issues.

Experts lay out considerations for expanding the administration’s proposed model beyond Medicare Part B drugs.